Page 18 - Pharmaceutical Firms

Glenmark gets USFDA nod to market generic version of Otezla tablets

Glenmark's current portfolio includes a total of 188 products that have been authorised for distribution in the US marketplace

Zydus Lifesciences appoints Punit Patel as president & CEO of Americas

Punit Patel will oversee the business operations of all Zydus entities in North America, including generics, injectables, specialty business, rare and orphan disease portfolio

Pharma result preview: US stable, India muted in the second quarter

Hospital occupancy rates rise 200-400 bps, while diagnostic sector sees seasonal benefits

FDA has accepted NDA for dermatological drug Deuruxolitinib: Sun Pharma

Sun Pharmaceutical Industries Ltd said that it had submitted an 8mg twice-daily regimen of deuruxolitinib for FDA review

Apotex seeks $118 million from Panacea for collaboration pact breach

Canada-based Apotex Inc has sought USD 118.14 million from Panacea Biotec over breach of a collaboration agreement inked in 2014, the capital-based drug firm said on Thursday. The company has received a notification dated October 4 from the International Court of Arbitration, Paris, intimating that an arbitration proceeding has been initiated as per a request by Apotex Inc, Panacea Biotec said in a regulatory filing. Apotex has alleged that the company has breached its obligations under the collaboration agreement for research, development, licence, supply and sale of products inked on May 9, 2014, it added. Apotex has alleged that there has been a purported delay in seeking approval from US Food and Drug Administration for the product mentioned in the said agreement, Panacea Biotec said. "Apotex has claimed USD 118.14 million towards outsized alleged losses plus interest thereon to the extent permissible under the applicable law," it added. The company believes it is not in breac

Stride Pharma Global receives USFDA approval or Efavirenz, other drugs

The company aims to launch about 60 new products in the next three years in the US market

Schedule M likely to be revised to bring it closer to WHO standards

The draft rules, still under consideration, include provisions to strengthen quality control and the safety of drugs manufactured in India

Medicine to manufacturing: Nano is the next frontier in 3D printing

Nano-level 3D printing can have various uses in medicine, like growing tissue cells to regenerate organs. Nano robots in bodies can attack cancer cells

Suven Pharma gets a new board as Advent International completes stake buy

Advent had announced the acquisition of a significant stake in Suven Pharma in December of the previous year from the Jasti family

Glenmark, Cosmo partner to bring acne treatment Winlevi to Europe, S Africa

This agreement grants Glenmark the exclusive right to commercialise Winlevi in 15 EU countries, South Africa, and the UK

Glenmark announces license agreements for Winlevi in Europe and S Africa

Cassiopea, a subsidiary of Cosmo, will receive an upfront payment of $5 million and agreed double-digit royalties on net sales

Pharma sector must focus on innovation to become global leader: Minister

Union health minister Mansukh Mandaviya on Tuesday asked domestic pharmaceutical industry to focus on the research and development of innovative products to move up the value chain and achieve global leadership. Mandaviya, who also holds the Chemical and Fertilisers portfolio, asked medical technology companies to produce critical equipment in India for the global markets. While formally unveiling the National Policy on Research & Development and Innovation in the Pharma-Med Tech Sector here, Mandaviya said the domestic pharmaceutical companies invest less on research and development when compared to multinational companies. "International MNCs spend 20-25 per cent of their profits in research and innovation while for Indian companies the average is around 10 per cent...Till the time we do not come out with research-led innovative products, we cannot lead the segment globally," he noted. He said the government wants to make the pharma industry self-reliant by 2047. "Today is a ...

Pharmaceutical firm Valiant Laboratories' IPO to open on September 27

Pharmaceutical ingredient manufacturing firm Valiant Laboratories has decided to launch its initial share sale for public subscription on September 27. The Initial Public Offering (IPO), which is an entirely fresh issuance of 1.08 crore equity shares with no offer for sale component, will be concluded on October 3, according to the red herring prospectus filed with Sebi on Friday. Further, bidding for anchor investors will open on September 26. Proceeds of the issue will be utilised to set up a manufacturing facility for speciality chemicals in Gujarat through its subsidiary -- Valiant Advanced Sciences Private Ltd. -- and to meet the working capital requirements of the subsidiary company. Valiant Laboratories is an active pharmaceutical ingredient or bulk drug manufacturing company with its focus on manufacturing paracetamol, which is used in the treatment of headache, muscle ache, arthritis, backache, toothache, cold and fever. The paracetamol API industry grew from Rs 2,200 cr

Lupin acquires five legacy brands from Meranini to solidify its portfolio

Lupin has already been marketing these brands in India since July 2021 under an agreement with A Menarini India Private Limited but will now have the full trademark ownership of the five brands

Genpharmasec to acquire 70% stake in DHPL in phased manner over one year

Incorporated in 1992, Generic Pharmasec Limited started as a manufacturer and trader of organic and inorganic chemicals, dyes, and pigments

Zydus Lifesciences gets USFDA nod for pregnancy prevention medication

The company said that this is the third hormonal transdermal patch to be approved from Zydus' generics portfolio

Taking corrective actions at Goa unit; stopped Digene production: Abbott

Drug maker Abbott on Thursday said it is implementing corrective actions at its Goa-based facility from where it had produced antacid Digene Gel that was recalled from the market due to non-compliance with manufacturing norms. Earlier this month, regulator DCGI cautioned against the consumption of Digene Gel citing safety concerns even as the drug maker recalled several batches of the medicine manufactured at the Goa facility. The drug regulatory body also advised doctors and healthcare professionals to carefully prescribe and educate their patients to discontinue the medicine's use and for reporting of any adverse drug reactions arising due to consumption of the said product. Goa FDA officials had conducted multiple inspections of the plant after the drug maker announced the recall of the antacid produced at the site and found various lapses of manufacturing norms, including hygiene issues, industry sources said. "We voluntarily stopped Digene manufacturing at our Goa site upon th

Sun Pharma, Pharmazz enter agreement to introduce Sovateltide in India

Sun Pharma said in a filing that it has been granted rights for marketing Sovateltide in India under the brand name Tyvalzi

Tabreed to invest $200 mn in Telangana to develop district cooling plants

Tabreed, a UAE-based global leader in cooling utilities, on Wednesday said it has partnered with Telangana government to develop cooling infrastructure for industrial and commercial parks, and will invest USD 200 million to develop 1,25,000 RT (refrigeration tonne) of district cooling plants for Hyderabad Pharma City. The state government also signed a MoU with Tabreed to explore district cooling infrastructure in existing and upcoming commercial districts of Cyberabad near here and other mixed use development areas. Speaking on the occasion, Telangana Urban Development, Industries and Commerce Minister K T Rama Rao said, "As we embark on a journey towards a more sustainable future, we are delighted to partner with Tabreed, exemplifying Government of Telangana's commitment to environmental stewardship through embracing innovative and implementable solutions." Tabreed chairman Khaled Abdulla Al Qubaisi said,"By bringing our expertise in district cooling to the world's largest net zer

Piramal-Bain investment arm acquires API biz of Ind-Swift for Rs 1,650 cr

The API business has a presence across the US, Japan, Korea, EU, Brazil, and India